Europe Next Generation Sequencing Market Analysis
The Next-Generation Sequencing (NGS) market in Europe is poised for significant expansion, with projections showing the market will grow from US$ 4.58 billion in 2023 to US$ 12.95 billion by 2032, reflecting a CAGR of 12.24% from 2024 to 2032. This robust growth is driven by advancements in genomic research, the rising demand for personalized medicine, and an increasing incidence of genetic disorders. As NGS technologies become more advanced, affordable, and accessible, they are reshaping the landscape of healthcare, research, and diagnostics across Europe.
Request a free sample copy of the report: https://www.renub.com/europe-next-generation-sequencing-market-p.php
Europe NGS Market Overview
Next-Generation Sequencing (NGS) is a high-throughput technology that allows for rapid sequencing of DNA and RNA. Compared to traditional sequencing methods, NGS can analyze millions of DNA fragments simultaneously, providing more comprehensive and accurate genetic information in a shorter amount of time and at a lower cost. The ability to decode vast amounts of genetic data has revolutionized several areas of research and healthcare, including cancer genomics, genetic disease diagnostics, personalized medicine, and infectious disease monitoring.
The European market for NGS is witnessing increased adoption in both clinical settings and research institutions, where it is being used to enhance diagnosis, improve patient care, and develop more effective treatment plans. The use of NGS in oncology, for example, allows for personalized cancer therapies tailored to the genetic profile of individual patients, improving treatment outcomes and minimizing side effects.
Key Growth Drivers of the Europe NGS Market
1. Advancements in Genomic Research
One of the major drivers behind the growth of the NGS market in Europe is the continuous advancement in genomic research. The ability to generate large-scale genomic data more efficiently has enabled researchers to discover new biomarkers and gain deeper insights into the genetic causes of diseases. Innovations in sequencing technologies have made these processes faster, cheaper, and more accurate, thereby making genomic research more accessible to a wider range of healthcare providers and research institutions.
These advancements are pivotal in the development of personalized medicine—a rapidly growing field in which treatment plans are tailored to a patient’s genetic makeup. With breakthroughs in genomic data analysis, scientists can identify genetic mutations responsible for diseases, leading to the development of targeted therapies that are more effective and have fewer side effects than traditional treatments.
2. Increasing Prevalence of Genetic Disorders
The growing incidence of genetic disorders across Europe is another key factor fueling the demand for NGS. Genetic disorders such as inherited cancers, rare diseases, and congenital conditions are becoming more prevalent, which increases the need for more precise diagnostic tools and treatments. NGS provides comprehensive genetic data that can pinpoint the exact mutations responsible for these disorders, enabling healthcare providers to offer more accurate diagnoses and personalized treatment plans.
For instance, NGS has shown great potential in diagnosing rare genetic diseases that are often difficult to detect using traditional methods. The technology enables healthcare professionals to identify even the most complex genetic conditions, speeding up the diagnostic process and improving patient outcomes.
3. Expanding Applications in Personalized Medicine
Personalized medicine, which involves tailoring medical treatments based on an individual’s genetic profile, is another significant driver of the NGS market in Europe. NGS plays a critical role in identifying genetic variations and understanding how they influence disease susceptibility, progression, and response to treatment.
By providing precise genetic information, NGS helps to guide clinicians in selecting the most appropriate treatment strategies, thus enhancing the effectiveness of medical interventions. This is particularly evident in oncology, where NGS is used to identify mutations in cancer-related genes, enabling the development of personalized cancer therapies that target specific genetic alterations in tumors.
As the demand for personalized medicine increases across Europe, more healthcare providers and pharmaceutical companies are investing in NGS technologies to improve their diagnostic and therapeutic capabilities.
4. Growth in Cancer Research and Diagnostics
Cancer research is one of the largest and most promising applications of NGS in Europe. With the increasing prevalence of cancer in the region, NGS has become an invaluable tool in cancer genomics. It helps researchers identify specific mutations, understand the molecular basis of different cancers, and develop personalized treatments.
In fact, the European Union has been investing heavily in research and development for cancer therapies. By 2030, the number of cancer cases in Europe is expected to rise to 4.9 million, up from 4.4 million in 2020. The need for effective cancer treatments and early diagnostics is pushing NGS to the forefront of oncology research, enabling clinicians to provide more accurate and individualized treatment options.
Regional Insights: Germany as a Key Player
Germany is one of the leading countries in the European NGS market, thanks to its strong research capabilities, investments in biotechnology, and a robust healthcare infrastructure. The country’s advanced healthcare system has integrated NGS into various medical applications, including cancer research, genetic disease diagnosis, and personalized medicine.
The demand for NGS in Germany is further driven by government grants and subsidies aimed at supporting genomic research and the development of innovative healthcare solutions. German research institutions and biotech firms are increasingly utilizing NGS to explore new biomarkers and genetic pathways associated with diseases, accelerating the development of novel therapies and diagnostic tools.
Germany is also leading the way in the adoption of sequencing-based tests in medical laboratories, with a growing emphasis on precision medicine. For example, in 2022, around 2,500 newborns were diagnosed with cystic fibrosis using NGS, demonstrating the widespread application of sequencing technologies in clinical settings.
Europe Next Generation Sequencing Market
Global Radiology Information System Market
Leading Companies in the European NGS Market
The European NGS market is highly competitive, with several major players driving innovation and market growth. Key companies operating in the region include:
- Illumina
- Thermo Fisher Scientific
- Pacific Biosciences of California
- QIAGEN N.V
- Roche
- Bio-Rad Laboratories, Inc.
- Takara Bio Inc.
- Hamilton Company
- Geneious
- BioMérieux SA
These companies are focusing on product innovation, strategic partnerships, and expanding their NGS service offerings to cater to the growing demand for genomic data and sequencing technologies across Europe.
Recent Developments and News
- Permanent Reimbursement for NGS in Oncology (July 2024): Belgium has introduced permanent reimbursement for NGS in oncology, further promoting the use of NGS technologies in cancer diagnosis and treatment.
- Almac Diagnostic Services Expansion (August 2023): Almac Diagnostic Services expanded its NGS capabilities for BioPharma partners by installing the Illumina NovaSeq™ X Plus instrument in Northern Ireland, marking a significant investment in the region’s genomic research capabilities.
- Illumina Integration of New Chemistry (June 2024): Illumina announced the integration of the new XLEAP-SBS™ chemistry into its NextSeq™ 1000 and NextSeq™ 2000 NGS instruments, further improving the performance and efficiency of sequencing workflows.
About the Company:
Renub Research is a Market Research and Consulting Company. We have more than 15 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.
Media Contact:
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)
Email: mailto:info@renub.com
